California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

Anthropic on Monday closed its latest funding round at a $61.5 billion post-money valuation, the company confirmed to CNBC.

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

We recently published an article titled Jim Cramer Discusses These 12 Stocks & Says Late Selloffs Are Deliberate. In this ...

Technology and Consumer Discretionary are the only two sectors down in the first two months of this year, among the 11 market ...

Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

Stifel downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 700, down from DKK 780. Novo is “no longer the same stock that ...

Goldman Sachs analysts added Novo Nordisk (NVO) to the firm’s European Conviction List as part of its monthly update. Novo Nordisk’s recent ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...